IONS, IBTA, IRDM: Cathie Wood Continues Trimming Stakes in Ionis, Ibotta, and Iridium Stocks

Cathie Wood made several notable sell-only moves across ARK ETFs on Friday, December 19, 2025, based on the daily trade filings. The filing shows ARK Invest continued cutting its stakes in some healthcare and technology stocks, with no new purchases reported for the day.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential What Stocks Did Cathie Wood Sell Today? The largest move of the day came from the ARK Genomic Revolution ETF (ARKG), which sold 8,928 shares of Ionis Pharmaceuticals (IONS). The transaction was valued at about $693,080. This followed Ionis sales earlier in the week, pointing to a steady cutback rather than a one-time trade. The hedge fund manager also continued trimming her position in consumer tech company Ibotta (IBTA). She sold 3,733 shares across her ARK Next Generation Internet ETF (ARKW) and the ARK Fintech Innovation ETF (ARKF) for a total value of about $81,379. ARK has been selling Ibotta shares throughout the week, signaling an ongoing exit. In addition, the flagship ARK Innovation ETF (ARKK) sold 226 shares of Iridium Communications (IRDM), a satellite company, valued at about $3,742. While small in size, the trade adds to recent Iridium sales and suggests a gradual reduction. Wall Street's Take on IONS, IBTA, and IRDM Using the TipRanks Stock Comparison Tool, we looked at how analysts currently view these stocks. Ionis Pharmaceuticals carries a Strong Buy rating with about 10% upside. Ibotta is rated Hold, despite nearly 30% upside to its price target. Meanwhile, Iridium holds a Moderate Buy rating and offers the highest upside, at roughly 51%.